RESUMO

Posaconazole (POS) is approved for prophylaxis of Aspergillus and Candida infections in immunocompromised patients and for the treatment of oropharyngeal candidiasis. Data is limited as step-down therapy after treatment with amphotericin B (AMB). Four cases with refractory mucormycosis who had a favorable response after a change in antifungal therapy to POS are presented. In these four patients, POS demonstrated to be an effective therapeutic option in the management of refractory mucormycosis. Further studies should be conducted to define its role, whether as a single agent or as adjuvant therapy in combination with AMB.

Assuntos

Antifúngicos/uso terapêutico , Mucormicose/tratamento farmacológico , Triazóis/uso terapêutico , Adulto , Humanos , Masculino , Pessoa de Meia-Idade